186Re-idarubicin

186Re-idarubicin is a **radiolabeled derivative of idarubicin**, where idarubicin, an anthracycline chemotherapeutic, is conjugated with rhenium-186. Idarubicin is a DNA-intercalating agent and topoisomerase II inhibitor, used primarily in the treatment of acute myeloid leukemia. Labeling idarubicin with rhenium-186 is intended to provide **targeted radiopharmaceutical chemotherapy**, combining the cytotoxic effects of idarubicin with the localized beta-emitting radiotherapeutic effects of rhenium-186. The compound is under early-stage investigation for use in cancer and is not approved for standard therapy. The radiolabeled agent is designed to enhance tumor cell kill through dual mechanisms: direct DNA damage from idarubicin and radiotoxicity from rhenium-186[3].